These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1374578)

  • 1. High-temperature short-time heat inactivation of HIV and other viruses in human blood plasma.
    Charm SE; Landau S; Williams B; Horowitz B; Prince AM; Pascual D
    Vox Sang; 1992; 62(1):12-20. PubMed ID: 1374578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of viruses in blood and plasma products.
    Suomela H
    Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658
    [No Abstract]   [Full Text] [Related]  

  • 4. Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates.
    Horowitz B; Prince AM
    Dev Biol Stand; 1987; 67():291-302. PubMed ID: 3609483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale purification of high purity α1-antitrypsin from Cohn Fraction IV with virus inactivation by solvent/detergent and dry-heat treatment.
    Huangfu C; Zhang J; Ma Y; Jia J; Li J; Lv M; Ma X; Zhao X; Zhang J
    Biotechnol Appl Biochem; 2018 May; 65(3):446-454. PubMed ID: 29072333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pasteurized therapeutic plasma.
    Burnouf-Radosevich M; Burnouf T; Huart JJ
    Infusionsther Transfusionsmed; 1992 Apr; 19(2):91-4. PubMed ID: 1623326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
    Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
    Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of viruses by pasteurization at 60 °C for 10 h with and without 40% glucose as stabilizer during a new manufacturing process of α2-Macroglobulin from Cohn Fraction IV.
    Huangfu C; Ma Y; Jia J; Lv M; Zhu F; Ma X; Zhao X; Zhang J
    Biologicals; 2017 Mar; 46():139-142. PubMed ID: 28215695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral inactivation vs biological activity.
    Barrowcliffe TW
    Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to produce virus-safe blood derivatives.
    Heimburger N; Karges HE
    Curr Stud Hematol Blood Transfus; 1989; (56):23-33. PubMed ID: 2910651
    [No Abstract]   [Full Text] [Related]  

  • 12. Virus inactivation by heat treatment of lyophilized coagulation factor concentrates.
    Piszkiewicz D; Thomas W; Lieu MY; Tse D; Sarno L
    Curr Stud Hematol Blood Transfus; 1989; (56):44-54. PubMed ID: 2491984
    [No Abstract]   [Full Text] [Related]  

  • 13. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of new viral infections: implications for the blood supply.
    Nathanson N
    Biologicals; 1998 Jun; 26(2):77-84. PubMed ID: 9811509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of parvovirus B19 genotype 2 in plasma products with different compositions in the inactivation sensitivity by liquid-heating.
    Tsujikawa M; Nishigaki H; Yoshikawa M; Furuki R; Takahashi K; Adan-Kubo J; Shimamura Y; Urayama T; Hattori S; Sakai K; Yunoki M; Ikuta K
    Vox Sang; 2012 Feb; 102(2):93-9. PubMed ID: 21781123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photochemical inactivation of viruses and bacteriophage in plasma and plasma fractions.
    Morel P; Lin L; Wiesehahn G; Corash L
    Blood Cells; 1992; 18(1):27-41; Discussion 41-2. PubMed ID: 1617190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors.
    Hiemstra H; Tersmette M; Vos AH; Over J; van Berkel MP; de Bree H
    Transfusion; 1991 Jan; 31(1):32-9. PubMed ID: 1898786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids.
    Horowitz B; Piët MP; Prince AM; Edwards CA; Lippin A; Walakovits LA
    Vox Sang; 1988; 54(1):14-20. PubMed ID: 2831669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.
    Uemura Y; Yang YH; Heldebrant CM; Takechi K; Yokoyama K
    Vox Sang; 1994; 67(3):246-54. PubMed ID: 7863623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virucidal heat-treatment of single plasma units: a potential approach for developing countries.
    Goubran HA; Burnouf T; Radosevich M
    Haemophilia; 2000 Nov; 6(6):597-604. PubMed ID: 11122382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.